Ethereum Price Prediction Eyes $3,500 Before $60K Macro Target
- ETH must reclaim $2,800 before $3,400 to $3,500 becomes credible.
- Crypto Patel maps $10,000 expansion and $60,000 macro bull targets.
- Ether ETFs lost about $155 million across four consecutive sessions.
Ethereum traded near $2,716 on October 5, holding above the $2,600 support area after September’s advance. The Ethereum price prediction now centers on whether ETH can close above $2,800 and reach $3,400-$3,500. Crypto Patel also outlined a longer-term $60,000 macro target, although that scenario requires several major resistance breaks.
Ethereum Price Prediction Tests $2,800 Breakout Resistance
ETH has remained above the $2,600-$2,635 support zone while consolidating near $2,700.
A strong weekly close above $2,800 could target $3,400-$3,500.
The broader Ethereum price prediction from Crypto Patel extends much further. The $60,000 level represents his macro bull case, not a near-term objective.
Ethereum Price Prediction Weighs ETF Outflows and Liquidity
The Ethereum price prediction also faces weaker institutional flows. U.S. spot Ether ETFs recorded about $155.12 million in net outflows across four sessions. BlackRock and Fidelity accounted for most withdrawals on the latest reported day.
Liquidity presents another constraint. CoinGecko measured ETH order-book depth near $13 million-$14 million close to the mid-price. That represented only 35%-45% of Bitcoin’s comparable depth across eight major exchanges.
The next Ethereum price prediction catalysts include the Glamsterdam Sepolia activation on October 6. The upgrade introduces proposer-builder separation and block-level access lists. Federal Reserve minutes arrive October 7 and could also influence crypto liquidity.
A loss of $2,600 would shift attention toward $2,480-$2,520. A confirmed break above $2,800 would strengthen the pathway toward $3,000 and $3,400-$3,500.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
